Copyright
©The Author(s) 2023.
World J Gastrointest Surg. May 27, 2023; 15(5): 906-916
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906
Table 5 Comparison of incidence rate of adverse reactions between the two groups, n (%)
| Group | Gastrointestinal reactions | Thrombus | Myelosuppression | Hepatic and renal impairment | Total incidence |
| Control group (n = 43) | 4 (9.30) | 1 (2.33) | 3 (6.98) | 1 (2.33) | 9 (20.94) |
| Observation group (n = 39) | 1 (2.56) | 0 (0) | 0 (0) | 1 (2.56) | 2 (5.12) |
| χ2 | 4.397 | ||||
| P value | 0.036 |
- Citation: Jiang YL, Fu XY, Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15(5): 906-916
- URL: https://www.wjgnet.com/1948-9366/full/v15/i5/906.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i5.906